LAG3 and classic Hodgkin lymphoma: Beyond CTLA-4, other emerging immune checkpoints under investigation in cHL include TIGIT (T-cell immunoreceptor with Ig and ITIM domains), LAG-3 (lymphocyte-activation gene 3), and CD47.